CDMO Almac adding 100 employees to its North Carolina site

CDMO Almac is adding a fourth building to its site in Durham, North Carolina. (Almac)

U.K.-based CDMO Almac is adding to its U.S. operations with a new building at its site in North Carolina where it says it will house 100 new employees.

The company Wednesday said the 24,000-square-foot office building will be its fourth at the Durham, North Carolina, site. The company declined to say precisely how much it is investing, but a spokesperson said in an email that it will be “multi millions” of dollars. The company will add the 100 workers over the next three years.

Almac last invested in the North Carolina clinical and diagnostic services operations in 2016 when it put $5.2 million into the facilities.  

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: CDMO Almac continues its expansion momentum with lab deal

The Northern Ireland-based company has been steadily expanding its global footprint. Also in 2016, it laid out plans for additions to several facilities, including a $25 million (£20 million) investment to expand its 240,000-square-foot offices at its U.S. headquarters in Souderton, Pennsylvania, and to lease a 26,000-square-foot office space in nearby Lansdale. Those projects were slated to add 312 jobs in the U.S.

Last year, it acquired BioClin Laboratories based in Athlone, Ireland, just two hours away from Almac Group’s headquarters in Craigavon. Almac said BioClin’s expertise and 14,000-square-foot facility significantly increased its analytical capacity and capabilities. It had already invested $6.3 million (£5 million) to build an additional laboratory and office facility at its headquarters.

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.